Drug Benefit List Reports

Welcome to the enhanced iDBL. The site has been enhanced with improved search features and a new look.

Menu

DBL Reports

Search the compilation of all issues (PDF) of all DBL Reports from April 1, 1999 to present (note: large file) or view separate issues listed below.

  • March 2024 – Issue #137
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed by CADTH
    • Highlights of Drug Products Added
    • Highlights of Changes to Currently Listed Products
    • Highlights of Interchangeable Drug Products Added
  • February 2024 – Issue #136
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed by CADTH
    • Highlights of Drug Products Added
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Special Authorization Criteria Changes
  • November 2023 – Issue #135
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed by CADTH
    • Highlights of Drug Products Added
    • Highlights of Interchangeable Drug Products Added
    • Addition of Single Source Drug Products
    • Special Authorization Criteria Changes
  • September 2023 – Issue #134
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed by CADTH
    • Highlights of Drug Products Added
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Highlights of Changes to Currently Listed Products
    • Special Authorization Criteria Changes
  • July 2023 – Issue #133
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed by CADTH
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Special Authorization Criteria Changes
  • May 2023 – Issue #132
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed by CADTH
    • Highlights of Biosimilar Drug Products Added
    • Special Authorization Criteria Changes
  • March 2023 – Issue #131
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed by CADTH
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Drug Products Added
  • February 2023 – Issue #130
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed by CADTH
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Highlights of Changes to Currently Listed Products
    • Special Authorization Criteria Changes
  • November 2022 – Issue #129
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed by CADTH
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Drug Products Added
    • Highlights of Changes to Currently Listed Products
    • Methadone Products
  • September 2022 – Issue #128
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed by CADTH
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Diabetes Supplies Added
    • Highlights of Drug Products Added
    • Special Authorization Criteria Changes
  • July 2022 – Issue #127
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Special Authorization Criteria Changes
  • May 2022 – Issue #126
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Diabetes Supplies Added
    • Highlights of Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Highlights of Changes to Currently Listed Products
    • Delisted Products
  • March 2022 – Issue #125
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Drug Products Added
    • Highlights of Changes to Currently Listed Products
  • February 2022 – Issue #124
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Highlights of Diabetes Supplies Added
    • Highlights of Drug Products Added
    • Highlights of Changes to Currently Listed Products
    • Delisted Products
  • November 2021 – Issue #123
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Highlights of Drug Products Added
    • Highlights of Changes to Currently Listed Products
  • September 2021 – Issue #122
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Drug Products Added
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Highlights of Changes to Currently Listed Products
    • Highlights of Diabetes Supplies Added
    • Special Authorization Criteria Changes
  • July 2021 – Issue #121
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Change of Listing Status
  • May 2021 – Issue #120
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Highlights of Drug Products Added
    • Special Authorization Criteria Changes
    • Delisted Products
  • March 2021 – Issue #119
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Biosimilar Drug Products Added
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Products Added
    • Special Authorization Criteria Changes
  • February 2021 – Issue #118
    • Brief Summary of Drug Review Activities
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Products Added
    • Change in Listing Status
    • Special Authorization Criteria Changes
  • November 1, 2020 – Issue #117
    • Brief Summary of Drug Review Activities
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Highlights of Line Extension Drug Product Added
    • Highlights of Actemra for GCA
    • Special Authorization Criteria Changes
  • September 1, 2020 – Issue #116
    • Brief Summary of Drug Review Activities
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Special Authorization Criteria Changes
  • July 1, 2020 – Issue #115
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Drug Products Added
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Biosimilar Drug Products Added
    • Special Authorization Criteria Changes
  • May 1, 2020 – Issue #114
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Line Extension Drug Products Added
    • Highlights of Interchangeable Drug Products Added
    • Special Authorization Criteria Changes
  • March 1, 2020 – Issue #113
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
  • February 1, 2020 – Issue #112
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Special Authorization Criteria Changes
  • November 1, 2019 – Issue #111
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Addition of Single Source Drug Products
  • September 1, 2019 – Issue #110
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Drug Products Added
    • Highlights of Interchangeable Drug Products Added
    • Restricted Benefit Criteria Changes
    • Special Authorization Criteria Changes
  • July 1, 2019 – Issue #109
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Line Extension Drug Products Reviewed for the ADBL
    • Special Authorization Criteria Changes
  • June 1, 2019 – Issue #108
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Drug Products Added
    • Special Authorization Criteria Changes
  • March 1, 2019 – Issue #107
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Drug Products Added
    • Highlights of Changes to Currently Listed Products
  • February 1, 2019 – Issue #106
    • Brief summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Drug Products Added
    • Highlights of Expedited Interchangeable Drug Products Added
    • Highlights of Interchangeable Drug Products Added
    • Step Therapy/Special Authorization Criteria Changes
  • November 1, 2018 – Issue #105
    • Brief Summary of Drug Review Activities
    • Highlights of Drug Products Added
    • Highlights of Interchangeable Drug Products Added
    • Changes in Listing Status and Criteria
  • September 1, 2018 – Issue #104
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Drug Products Added
    • Highlights of Expedited Interchangeable Drug Products Added
    • Highlights of Interchangeable Drug Products Added
    • Special Authorization criteria changes
    • Non-Innovator Policy Review
  • July 1, 2018 – Issue #103
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Drug Products Added
    • Highlights of Expedited Interchangeable Drug Products Added
    • Special Authorization Criteria Changes
    • Changes in listing status
    • Non-Innovator Policy Review
  • May 1, 2018 – Issue #102
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Drug Products Added
    • Highlights of Expedited Interchangeable Drug Products Added
    • Special Authorization Criteria Changes
  • March 1, 2018 - Issue #101
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Drug Products Added
    • Highlights of Changes to Currently Listed Products
    • Restricted Benefit Criteria Changes
    • Special Authorization Criteria Changes
  • February 1, 2018 - Issue #100
    • 100th Issue of DBL Report
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Drug Products added
    • Highlights of IC Drug Products added
    • Special Authorization Criteria Changes
  • November 1, 2017 - Issue #99
    • Brief Summary of Drug Review Activities
    • Highlights of:
    • Products Originally Reviewed via the CDR
    • Line Extension Drug Products
    • Expedited IC Drug Products added
    • IC Drug Products added
    • Other Drug Products added
    • Changes to currently listed products
  • September 1, 2017 - Issue #98
    • Brief Summary of Drug Review Activities
    • Highlights of Products originally reviewed via the CDR
    • Highlights of Drug Products added
    • Highlights of Expedited IC Drug Products added
    • Highlights of IC Drug Products added
    • Special Authorization criteria changes
    • Restricted Benefit cirteria changes
  • July 1, 2017 - Issue #97
    • Brief Summary of Drug Review Activities
    • Highlights of Products originally reviewed via the CDR
    • Highlights of Devices added
    • Highlights of Interchangeable Drug Products added
    • Highlights of Non-Interchangeable Old Drug Products added
  • May 1, 2017 - Issue #96
    • Brief Summary of Drug Review Activities
    • Highlights of Products originally reviewed via the CDR
    • Highlights of Drug products added
    • Highlights of Interchangeable drug products reviewed
    • Highlights of Other products reviewed but not added
    • Special Authorization Criteria Changes
  • February 1, 2017 - Issue #95
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products added
    • Highlights of Other Products Added
    • Changes in Listing Status
    • Special Authorization Criteria Changes
  • November 1, 2016 - Issue #94
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Other Products Added
    • Maximum Allowable Cost (MAC) New Category
  • September 1, 2016 - Issue #93
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Other Products Added
  • July 1, 2016 - Issue #92
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Interchangeable Drug Products added
    • Special Authorization Criteria Changes
  • May 1, 2016 - Issue #91
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Non-Interchangeable Old Drug Products
    • Highlights of Line Extension Drug Products Reviewed for the ADBL
    • Highlights of Other Products Reviewed but Not Added
    • Highlights of Interchangeable Drug Products Reviewed
    • Highlights of Other Products Added
    • Highlights of New Interchangeable Groupings
    • Special Authorization Criteria Changes
  • March 1, 2016 - Issue #90
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Devices Added
    • Highlights of Line Extension Drug Products
    • Highlights of Other Drug Products Reviewed but Not Added
    • Highlights of Interchangeable Drug Products Reviewed
    • Highlights of Natural Health Products Reviewed
    • Highlights of Change in Listing Status
  • February 1, 2016 - Issue #89
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Line Extension Products
    • Highlights of Other Products Reviewed but Not Added
    • Highlights of Interchangeable Drug Products Reviewed
    • Special Authorization Criteria Changes
    • ROBS Review of Growth Hormone Products
  • November 1, 2015 - Issue #88
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Non-Interchangeable Old Drug Products
    • Highlights of Line Extension Products
    • Highlights of Other Products Reviewed but Not Added
    • Highlights of Interchangeable Drug Products Reviewed
    • Highlights of Product Listing Changes
    • Special Authorization Criteria changes
  • September 1, 2015 - Issue #87
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Other Products Reviewed but Not Added
    • Highlights of Interchangeable Drug Products Added
    • Special Authorization Criteria Changes
  • July 1, 2015 - Issue #86
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the Common Drug Review (CDR)
    • Highlights of Products Not Added
    • Highlights of Non-Interchangeable Old Drug Products Added
    • Highlights of Line Extension Drug Products Reviewed for Addition to the ADBL
    • Highlights of Interchangeable Drug Products Added
    • Highlights of Drug Products De-Listed from the ADBL
    • Special Authorization Criteria Changes
  • May 1, 2015 - Issue #85
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Line Extension Drug Products Added to the ADBL
    • Highlights of Natural Health Products Not Added
    • Special Authorization Criteria Changes
  • April 1, 2015 - Issue #84
      Brief Summary of Drug Review Activities Updates to the Manufacturer Submission Requirements Highlights of Products Originally Reviewed via the CDR Highlights of Drug Products Added Highlights of LE Drug Products Added to the ADBL Highlights of LE Drug Products Not Added to the ADBL Highlights of IC Drug Products Not Added Special Authorization Criteria Changes
  • February 1, 2015 - Issue #83
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the Common Drug Review (CDR)
    • Highlights of Drug Products Added
    • Highlights of Line Extension Drug Products Reviewed for Addition to the ADBL
    • Highlights of Interchangeable (IC) Drug Products Added
    • Highlights of Interchangeable Drug Products Not Added
    • Highlights of Non-Interchangeable Old Drug Products (NICOD) Not Added
    • Special Authorization Criteria Changes
    • Changes in Benefit Status due to product discontinuation
  • November 1, 2014 - Issue #82
    • Brief Summary of Drug Review Activities
    • Highlights of Interchangeable (IC) Drug Products Added
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Changes to Currently Listed Products
    • Highlights of Interchangeable Drug Products Not Added
    • Highlights of Other Changes to the ADBL
  • September 1, 2014 - Issue #81
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Entry Interchangeable (IC) Drug Products Added
    • Highlights of Non-Interchangeable Old Drug Products Not Added
    • Highlights of Line Extension Drug Products Reviewed by the Expert Committee
  • July 1, 2014 - Issue #80
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Single Source Drug Products Added
    • Highlights of Entry Interchangeable (IC) Drug Products Added
    • Highlights of Non-Interchangeable Old Drug Products Not Added
    • Highlights of Line Extension Drug Products Added
    • Aranesp and Eprex Special Authorization Criteria Changes
  • May 1, 2014 - Issue #79
    • Brief Summary of Drug Review Activities
    • Highlights of Line Extension Drug Products Added
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Products not Added
    • Highlights of Non-Interchangeable Old Drug Products Added
    • Highlights of Entry Interchangeable (IC) Drug Products Added
    • Vimpat Special Authorization Criteria Changes
    • Leflunomide Restricted Benefit Criteria Changes
  • March 1, 2014 - Issue #78
    • Brief Summary of Drug Review Activities
    • Highlights of Line Extension Drug Products Added
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Expedited IC Products Added
    • Highlights of IC Drug Products added
    • Neupogen and Neulasta Special Authorization Criteria Changes
    • Eliquis Listing Status Update
  • February 1, 2014 - Issue #77
    • Brief Summary of Drug Review Activities
    • Highlights of Line Extension Drug Products Added
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of IC Drug Products added
    • Highlights of NICOD Products Added
    • Highlights of Deferrals
    • Benefit Coverage and SA Criteria Changes for Osteoporosis Medications
    • ROBS Review - Beta-Blockers
  • November 1, 2013 - Issue #76
    • Brief Summary of Drug Review Activities
    • Highlights of Drug Products Added
    • Highlights of Line Extension Drug Products Added
    • Highlights of Natural Health Products Added
    • Highlights of Non-IC Old Drug Products Added
    • Highlights of Expedited IC Drug Products added
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of IC Drug Products Added
    • Highlights of SA Criteria Changes
  • September 1, 2013 - Issue #75
    • Brief Summary of Drug Review Activities
    • Highlights of Line Extension Drug Products Added
    • Highlights of Expedited IC Drug Products Added
    • Highlights of Products Originally Reviewed via the CDR
    • Highlights of Drug Products not Added
    • Highlights of Criteria Changes
    • Risk of Hypoglycemia with Anti-diabetic Agents
  • July 1, 2013 - Issue #74
    • Brief Summary of Drug Review Activities
    • Highlights of New Products Added
    • Highlights of Products Originally Reviewed via the Common Drug Review (CDR)
    • Highlights of IC Drug Products Added
    • Highlights of Natural Health Products Added
    • Highlights of Line Extension Drug Products Added
    • Highlights of Criteria Changes
  • June 1, 2013 - Issue #73
    • Brief Summary of Drug Review Activities
    • Highlights of New Products Added
    • Highlights of Products Originally Reviewed via the Common Drug Review (CDR)
    • Highlights of Established IC Drug Products Added
    • Highlights of Natural Health Products Added
    • Highlights of Criteria Changes
    • Follow-up: Pre-Requisite Medications for Biologic Coverage
  • March 1, 2013 - Issue #72
    • Brief Summary of Drug Review Activities
    • Highlights of Products Originally Reviewed via the Common Drug Review (CDR)
    • Highlights of Expedited Entry IC Drug Products Added
    • Highlights of Established IC Drug Products Added
    • Highlights of Other Additions to the ADBL
    • Coverage of Controlled Release Oxycodone Drug Products
  • February 1, 2013 - Issue #71
    • Brief Summary of Drug Review Activities
    • Products Originally Reviewed via the Common Drug Review (CDR)
    • Highlights of Products Added to the ADBL
    • Highlights of Entry IC Products Added
    • Highlights of Established IC Products Added
    • Highlights of Expedited Entry IC Products Added
    • Highlights of Motherisk Guidance on Pre-Requisite Medications
  • November 1, 2012 - Issue #70
    • Brief Summary of Drug Review Activities
    • Highlights of Products Added to the ADBL
    • Highlights of Entry IC Products Added
    • Highlights of Expedited Entry IC Products Added
    • Products of Originally Reviewed via the Common Drug Review (CDR)
    • Changes in SA Criteria for Clopidogrel
  • September 1, 2012 - Issue #69
    • Brief Summary of Drug Review Activities
    • Highlights of Products Added
    • Highlights of IC Products Added
    • Highlights of Products not Added
    • Highlights of Changes in MS Drug Coverage
    • Products Originally Reviewed via the Common Drug Review (CDR)
  • August 1, 2012 - Issue #68
    • Brief Summary of Drug Review Activities
    • Diabetic Self-management Supplies
    • Highlights of Products added to the ADBL
  • May 1, 2012 - Issue #67
    • Brief Summary of Drug Review Activities
    • Products Originally Reviewed via the Common Drug Review (CDR)
    • Highlights of New IC Groupings
    • Other Products added to the ADBL
  • March 1, 2012 - Issue #66
    • Brief Summary of Drug Review Activities
    • Highlights of New Products Added
    • Highlights of New Interchangeable (IC) Groupings
    • Highlights of Benefit Coverage and Criteria Changes
    • Additional Products Originally Reviewed via the Common Drug Review (CDR)
  • February 1, 2012 - Issue #65
    • Brief Summary of Drug Review Activities
    • Highlights of New IC Groupings
    • Highlights of Products Not Added
    • Highlights of IC Products Added
    • Highlights of Additional Products Added
  • November 1, 2011 - Issue #64
    • Brief Summary of Drug Review Activities
    • Product Originally Reviewed via the Common Drug Review (CDR)
    • Highlights of New IC Groupings
    • Highlights of Products Not Added
    • Highlights of New Products Added
  • September 1, 2011 - Issue #63
    • Brief Summary of Drug Review Activities
    • Products Originally Reviewed via the Common Drug Review (CDR)
    • Highlights of New Products Added
    • Highlights of New IC Groupings
    • Highlights of Special Authorization (SA) Criteria Changes
  • July 1, 2011 - Issue #62
    • Brief Summary of Drug Review Activities
    • Products Originally Reviewed via the Common Drug Review (CDR)
    • Osteoporosis
    • Products Not Added
    • Highlights of New Interchangeable (IC) Groupings
  • May 1, 2011 - Issue #61
    • Brief Summary of Drug Review Activities
    • Highlights of New Products Added
    • Highlights of New Interchangeable (IC) Groupings
    • Review of Benefit Status (ROBS) Process
    • Products Originally Reviewed via the Common Drug Review (CDR)
  • March 1, 2011 - Issue #60
    • Brief Summary of Drug Review Activities
    • Highlights of New Products Added
    • Highlights of New IC Groupings
    • Alzheimer's Disease SA Drug Products
    • Highlights of Special Authorization (SA) Criteria Changes
    • Did You Know...?
  • February 1, 2011 - Issue #59
    • Brief Summary of Drug Review Activities
    • Highlights of New Products Added
    • Special Authorization Criteria Changes
  • November 1, 2010 - Issue #58
    • Brief Summary of Drug Review Activities
    • Highlights of New Products Added
    • Special Authorization Criteria Changes
  • September 1, 2010 - Issue #57
    • Brief Summary of Drug Review Activities
    • Highlights of Products Added
    • Special Authorization Criteria Changes
    • Changes in Benefit Status
    • New IC Groupings
    • Products Originally Reviewed via the Common Drug Review (CDR)
    • Product Not Added
  • July 1, 2010 - Issue #56
    • Highlights of Products Added
    • Highlights of New IC Groupings
    • Highlights of Products Not Added
    • Products Originally Reviewed via the Common Drug Review (CDR)
  • April 1, 2010 - Issue #55
    • Highlights of New Products Added
    • Highlights of Coverage Criteria Changes
    • Highlights of Interchangeable Products Added
    • Highlights of Products Not Added
    • Change to Botox Unit of Issue
    • Reinstatement of Premarin Tablets
    • Orencia for Juvenile Idiopathic Arthritis
    • ROBS Review of Insulins and Oral Anti-Diabetic Agents
    • Fucithalmic De-Listed
    • Updated Price Policy
    • Expedited Review for Interchangeable Products & Revised Submission Requirements
  • October 1, 2009 - Issue #54
    • Highlights of Products Added
    • Highlights of Interchangeable Products Added
    • De-Listing of Premarin Tablets
    • Special Authorization Criteria Change for Avodart & Proscar
  • July 1, 2009 - Issue #53
    • Highlights of Products Added
    • Highlights of Interchangeable Products
    • Change in Benefit Status of Cyclobenzaprine 10 mg tablets
    • Highlights of Products Not Added
  • May 1, 2009 Update- Issue #52
    • Application of Least Cost Alternative to Gen-Clozapine 25 mg and 100 mg
  • April 1, 2009 - Issue #51
    • Highlights of Products Added
    • Highlights of Restricted Benefits Added
    • Highlights of Changes in Benefit Status or Coverage Criteria: Aggrenox, Aldara, Levetiracetam products, Humira, Rituxan, Biologics for RA and Chronic Hepatitis B drugs
  • January 1, 2009 - Issue #50
    • Highlights of New Products Added
    • Highlights of Products Not Added
    • Highlights of Special Authorization Products Added
  • October 1, 2008 - Issue #49
    • New Products Added
    • Interchangeable Products Added August 1, 2008
    • Products Not Added
    • Changes to Special Authorization Criteria for Medications Used in the Treatment of Alzheimer’s Disease
  • July 1, 2008 - Issue #48
    • Highlights of Products Not Added
    • Highlights of Changes to Benefit Status
    • Highlights of New Products Added
    • Highlights of Interchangeable Products Added May 1, 2008
  • April 1, 2008 - Issue #47
    • Highlights of New Products Added
    • Highlights of Products Not Added
    • Highlights of Changes to Benefit Status
    • Highlights of Interchageable Products Added February 1, 2008
  • January 1, 2008 - Issue #46
    • Highlights of New Products Added
    • Highlights of Interchangeable Products Added
    • Highlights of Products Not Added
    • Special Authorization Criteria Change: Ketek
  • October 1, 2007 - Issue #45
    • Highlights of New Products Added
    • Highlights of Special Authorization Products Added
    • Highlights of Interchangeable Products Added
    • Special Authorization Criteria Change: Aranesp and Eprex
    • Changes in Benefit Status: Glaucoma Treatments; Antiviral Agents
  • July 1, 2007 - Issue #44
    • Highlights of New Products Added
    • Highlights of Special Authorization Products Added
    • Highlights of Special Authorization Criteria Changes
    • Highlights of Products not Added
    • Changes in Benefit Status; Salbutamol 2 mg/mL (base) inhalation unit dose solutions, Eumovate topical cream
  • April 1, 2007 - Issue #43
    • Highlights of Products Added
    • Changes in Benefit Status of vaginal anti-infective products, parasympathomimetics, papaverine and Intron A
    • Highlights of Products Added via Special Authorization
    • Highlights of Products Not Added
  • January 1, 2007 - Issue #42
    • Highlights of Products Added
    • Highlights of Products Added via Special Authorization
    • Highlights of Products Added to MS Drug Coverage Program
    • Highlights of Products Not Added
    • Change in Benefit Status of Topical Antibiotic, EENT Antibiotic Products and Stemgen
  • October 1, 2006 - Issue #41
    • Highlights of Products Added
    • Highlights of Changes to Special Authorization Criteria
    • Highlights of Products Added via Special Authorization
    • Highlights of Products Not Added
    • Special Authorization Criteria Change for Drugs Used in the Treatment of Alzheimer's Disease
  • July 1, 2006 - Issue #40
    • Highlights of Products Added
    • Special Authorization Criteria Change for Duragesic Transdermal Patches Change
    • in Benefit Status of EENT Anti-Allergy Products
    • Review of Benefit Status of Plavix
    • Highlights of Products Not Added
    • Removal of Interchangeability Designation of Novo-Bupropion SR 150 mg Tablets
  • April 1, 2006 - Issue #39
    • Highlights of New Products Added
    • Highlights of Interchangeable Products Added
    • Highlights of Products Not Added
    • New Criterion for Optional Special Authorization of Select Quinolones
    • Special Authorization Criteria Change for Alzheimer's Drugs
  • January 1, 2006 - Issue #38
    • Highlights of New Products Added
    • Highlights of Interchangeable Products Added
    • Highlights of Products Not Added
    • Topical Products Used in the Treatment of Acne
    • Optional Special Authorization (OSA)
  • October 1, 2005 - Issue #37
    • Highlights of New Products Added
    • Highlights of Interchangeable Products Added
    • Highlights of Special Authorization Criteria Changes
    • Neulasta Addition
    • Neupogen Criteria Change
  • July 1, 2005 - Issue #36
    • Highlights of New Products Added
    • Highlights of Special Authorization Criteria Changes
    • Highlights of Interchangeable Products Added
    • Review of Benefit Status (ROBS) Process
    • Common Drug Review Product
  • April 1, 2005 - Issue #35
    • Cancidas Added via Special Authorization
    • Highlights of New Products Added
    • Highlights of Products Not Added
    • Selective COX-2 Inhibitors: Emerging Safety Concerns
    • Bacid Removed from the ADBL
  • January 1, 2005 - Issue #34
    • Highlights from the Review of Antimicrobials
    • Highlights of Products Added
    • Additional Highlights
  • October 1, 2004 - Issue #33
    • Highlights of New Products Added
    • Highlights of Products Not Added
    • Products Removed from the ADBL
    • Pegetron Special Authorization Criteria
  • July 1, 2004 - Issue #32
    • Highlights of New Products Added
    • Highlights of Products Not Added
    • Enbrel for Polyarticular Juvenile Rheumatoid Arthritis
    • Changes to Special Authorization Coverage of Select Products for the Treatment of Hepatitis C
  • April 1, 2004 - Issue #31
    • Highlights of New Products Added
    • Highlights of Interchangeable Products Added
    • Highlights of Products Not Added
    • Changes to Special Authorization Criteria for Drugs used in
    • Alzheimer’s Disease
    • Changes to Special Authorization Criteria for Pegetron
    • The Rationale Behind Special Authorization (SA)
  • January 1, 2004 - Issue #30
    • Highlights of Products Added via Special Authorization
    • Highlights of Products Added
    • Highlights of Products Not Added
    • Novo-Alendronate 10 mg tablets
    • Changes to Special Authorization Criteria for Actos
  • October 1, 2003 - Not issued
  • July 1, 2003 - Issue #29
    • Highlights of New Products Added
    • Highlights of Additional Strengths and Formulations of Products
    • Available via Special Authorization
    • Highlights of Deferred Products
    • Highlights of Products Not Added
    • Products Designated as Interchangeable
    • Alberta Post-Marketing Study for Enbrel and Remicade
  • April 1, 2003 - Issue #28
    • Highlights of New Products Added
    • Highlights of Deferred Products
    • Highlights of Products Not Added
    • Changes to the Special Authorization Criteria for Nitoman
    • Changes to the Benefit Status of Detrol
    • Changes to the Special Authorization Criteria for Evista
  • January 1, 2003 - Issue #27
    • Highlights of New Products Added
    • Changes to the Benefit Status of Andriol
    • Highlights of Deferred Products
    • Highlights of Products Not Added
    • Highlights of Interchangeable Products added
  • October 1, 2002 - Update Issue #26
    • Flovent HFA Added
  • October 1, 2002 - Issue #25
    • Highlights of New Products Added
    • Highlights of Deferred Products
    • Highlights of Products Not Added
    • Devices Added to the ADBL as Restricted Benefit
  • July 1, 2002 - Issue #24
    • Highlights of New Products Added
    • Highlights of Deferred Products
    • Highlights of Products Not Added
    • Update: Status of TNF-Antagonists
  • April 1, 2002 - Issue #23
    • Highlights of New Products Added
    • Update: Removal of the LCA Policy from Methotrexate Sodium 25 mg/mL Preserved and Unpreserved Injectable Products
    • Highlights of Changes to SA Criteria
    • Highlights of Deferred Products
    • Highlights of Products Not Added
  • January 1, 2002 - Issue #22
    • Highlights of the Review of SA Drugs Used in the Treatment of Osteoporosis
    • Highlights of New Products Added
    • Highlights of Changes to SA Criteria
    • Highlights of Deferred Products
    • Interchangeability and Application of LCA to Methotrexate Sodium 25 mg/mL (base) Injection
    • Highlights of Products Not Added
  • December 1, 2001 - Update
    • Interchangeability of Warfarin Sodium Preparations
  • October 1, 2001 - Issue #21
    • Highlights of New Products Added
    • Highlights of New Products Added via Special Authorization (SA)
    • SA Criteria for Antiplatelet Agents
    • Highlights of Products Not Added
  • August 1, 2001 - Issue #20
    • Highlights of New Products Added via Special Authorization (SA)
    • Changes in SA Criteria
    • New LCA Products Added
    • Highlights of Products Deferred
    • Highlights of Products Not Added
  • April 1, 2001 - Issue #19
    • Highlights of New Products Added
    • Changes of Special Authorization (SA)
    • Highlights of Products Not Added
    • Expert Committee Profiles: Dr. Norman R.C. Campbell
    • Changes in SA Renewal Policy for Selected Products
  • January 1, 2001 - Issue #18
    • Products for Osteoporosis Added via Special Authorization
    • Products for Type 2 Diabetes Mellitus Added via Special Authorization
    • Additional Products Added via Special Authorization
    • Highlights of New Products Added
    • Highlights of Products Not Added
  • December 1, 2000 - Update
    • Interchangeability of Warfarin Sodium Preparations
  • October 1, 2000 - Issue #17
    • Changes in Special Authorization Criteria
    • Special Authorization for Cerezyme
    • Highlights of New Products Added
    • Expert Committee Profiles: Dr. Stephen C. Newman
    • Highlights of Deferred Products
  • July 1, 2000 - Issue #16
    • Change in Benefit Status
    • Highlights of New Products Added
    • Highlights of Deferred Products
    • Highlights of Products Not Added
    • Expert Committee Profiles: Dr. Judith Baker
    • Products Removed from the ADBL
  • April 1, 2000 - Issue #15
    • Highlights of New Products Added
    • Highlights of Deferred Products
    • Highlights of Products Not Added
    • Clarification on Aricept Special Authorization (SA) Criteria
    • Products Removed from the ADBL
  • January 1, 2000 - Issue #14
    • Highlights of New Products Added
    • Highlights of Deferred Products
    • Expert Committee Profiles: Dr. James Silvius
    • Why are drug products under review not eligible for special
    • authorization or made available on an exception basis?
  • October 1, 1999 - Issue #13
    • Highlights of New Products 'Fast-Tracked'
    • New LCA Products Added
    • Highlights of Products Added and Not-Added
  • April 1, 1999 - Update
    • Interchangeability of Levothyroxine Sodium Preparations
  • April 1, 1999 - Issue #12
    • Highlights of New Products Added
    • Highlights of Products Not Added

Notice:

The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.

Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross® who publishes them on behalf of Alberta Health and Alberta Human Services.

Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL (iDBL), and any such changes to the Interactive DBL (iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.